News of Note—Biotech IPOs; CHMP knockbacks

> Vanda Pharmaceuticals has seen the European Medicines Agency once again knock back its schizophrenia antipsychotic Fanaptum (iloperidone). The CHMP, the safety and efficacy arm of the European regulator, said its effectiveness was “modest,” that it took too long to work and also had CV and toxicity safety concerns. It was previously rejected by the CHMP back in 2012. CHMP decision (PDF)

> And Vanda was not the only biopharma to see a rejection during this month’s CHMP decisions: Nektar Therapeutics and partner Daiichi’s advanced breast cancer med Onzeald (etirinotecan pegol) also failed to win recommendation. The CHMP said it didn’t think Nektar has done enough to show the med works in this setting. CHMP decision (PDF)

> While 2016 was pretty dire for IPOs, as we delve deeper into 2017 biotech public offerings are bouncing back, with two announced today. First up is Genprex, a gene therapy company looking to list on the Nasdaq and use the cash to fund work on its Oncoprex immunogene therapy, which is targeting non-small cell lung cancer. SEC filing


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

> The second IPO-seeking biotech, which wants a $100 million IPO, is OrbiMed and New Enterprise Associates-backed Clementia Pharmaceuticals. Its lead product candidate, palovarotene, is an oral small molecule that binds and activates retinoic acid receptor gamma. The drug is in clinical testing for the rare disorders fibrodysplasia ossificans progressiva and multiple osteochondroma, with data readouts expected by the end of the decade. SEC filing

Suggested Articles

The FDA has cleared Drawbridge Health’s blood collection device designed to help monitor long-term blood sugar levels in people with diabetes.

Rachel Humphrey, M.D., who joined CytomX as chief medical officer after heading immuno-oncology at AstraZeneca and Eli Lilly, has made her exit.

FierceMedTech Fierce 15 winner 10x Genomics announced its plans for a $100 million IPO, on the Nasdaq using the symbol TXG.